Century Therapeutics, Inc. (IPSC)

Market Cap	204.51M
Revenue (ttm)	2.24M
Net Income (ttm)	-136.67M
Shares Out	64.92M
EPS (ttm)	-2.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	115,934
Open	2.880
Previous Close	2.960
Day's Range	2.850 - 3.180
52-Week Range	1.280 - 5.510
Beta	1.34
Analysts	Strong Buy
Price Target	14.00 (+344.44%)
Earnings Date	May 9, 2024

About IPSC

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relaps...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 18, 2021
• Employees: 152
• Stock Exchange: NASDAQ
• Ticker Symbol: IPSC

Financial Performance

In 2023, IPSC's revenue was $2.24 million, a decrease of -57.01% compared to the previous year's $5.20 million. Losses were -$136.67 million, 4.38% more than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for IPSC stock is "Strong Buy." The 12-month stock price forecast is $14.0, which is an increase of 344.44% from the latest price.

Price Target

$14.0

(344.44% upside)

Analyst Consensus: Strong Buy